Lixte Biotechnology Holdings is a clinical-stage pharmaceutical company focused on oncology, including PP2A inhibitor-based therapies such as LB-100. The company develops cancer treatments and runs multiple clinical programs for solid tumors.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary to lead advancement of the LiGHT System proton therapy platform following the company's November 2025 acquisition of Liora's assets.
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness across multiple cancer types, with proof-of-concept trials underway.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06065462 |
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 |
RECRUITING | PHASE1/PHASE2 |
